Humacyte (HUMA) Competitors

Humacyte (NASDAQ:HUMA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Does the media prefer HUMA or COLL?

In the previous week, Humacyte had 5 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 11 mentions for Humacyte and 6 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.05 beat Humacyte's score of 0.95 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in HUMA or COLL?

44.7% of Humacyte shares are held by institutional investors. 11.2% of Humacyte shares are held by insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable earnings & valuation, HUMA or COLL?

Collegium Pharmaceutical has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$1.57M	145.73	-$110.78M	-$1.26	-1.17
Collegium Pharmaceutical	$631.45M	1.37	$48.15M	$1.86	14.49

Is HUMA or COLL more profitable?

Collegium Pharmaceutical has a net margin of 14.78% compared to Humacyte's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	N/A	-942.81%	-93.82%
Collegium Pharmaceutical	14.78%	104.67%	18.38%

Which has more volatility & risk, HUMA or COLL?

Humacyte has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Do analysts prefer HUMA or COLL?

Humacyte presently has a consensus price target of $13.71, suggesting a potential upside of 829.78%. Collegium Pharmaceutical has a consensus price target of $43.60, suggesting a potential upside of 61.78%. Given Humacyte's stronger consensus rating and higher probable upside, research analysts plainly believe Humacyte is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Does the MarketBeat Community believe in HUMA or COLL?

Collegium Pharmaceutical received 351 more outperform votes than Humacyte when rated by MarketBeat users. However, 70.18% of users gave Humacyte an outperform vote while only 65.49% of users gave Collegium Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Humacyte	Outperform Votes 40 70.18%	Underperform Votes 17 29.82%
Collegium Pharmaceutical	Outperform Votes 391 65.49%	Underperform Votes 206 34.51%

Summary

Humacyte beats Collegium Pharmaceutical on 10 of the 19 factors compared between the two stocks.